67/100B706.32
USD
7.96
(1.14%)
Post Trading·709.98USD+3.66(+0.52%)
Last updated: · Delayed 15 min
Fair value599.09Plus+18%433Price 706.32754
Q4 FY2026 · Earnings report
EPS estimate 7.13Revenue estimate 12.84B
Q4 FY2026 · Earnings report
EPS estimate 7.13Revenue estimate 12.84B
Thermo Fisher Scientific financials
Yes. Thermo Fisher Scientific earned 7.08B USD of net income over the last twelve months, 15.0% of its revenue. It made a profit in 38 of its 41 fiscal years since 1985. Its last loss was in fiscal year 2001.
- Revenue (TTM)
- 47.35B USD
- Net income (TTM)
- 7.08B USD
- Free cash flow (TTM)
- 7.60B USD
- Cash and short-term investments
- 6.06B USD
- Total debt
- 41.37B USD
- Shareholders' equity
- 54.76B USD
Cash, debt and equity as of 26 Sept 2026.
Thermo Fisher Scientific earnings
Next earnings · Q4 FY2026
EPS estimate
7.13 USD
Revenue estimate
12.84B USD
Last quarter · Q3 FY2026
EPS6.68Beat +4.4%Revenue12.14BBeat +1.5%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 7.15 | — | — | +6.96% | 12.68B | — | — | +4.49% | |
| Q2 FY2027 | 6.62 | — | — | +9.77% | 12.46B | — | — | +3.85% | |
| Q1 FY2027 | 6.06 | — | — | +11.36% | 11.74B | — | — | +6.70% | |
| Q4 FY2026 | 7.13 | — | — | +8.52% | 12.84B | — | — | +5.14% | |
| Q3 FY2026 | 6.40 | 6.68 | +4.37% | +15.37% | 11.95B | 12.14B | +1.54% | +9.13% | |
| Q2 FY2026 | 5.72 | 6.03 | +5.42% | +12.50% | 11.71B | 11.99B | +2.46% | +10.49% | |
| Q1 FY2026 | 5.25 | 5.44 | +3.62% | +5.63% | 10.86B | 11.01B | +1.29% | +6.18% | |
| Q4 FY2025 | 6.45 | 6.57 | +1.86% | +7.70% | 11.95B | 12.22B | +2.22% | +7.20% | |
| Q3 FY2025 | 5.50 | 5.79 | +5.27% | +9.66% | 10.92B | 11.12B | +1.87% | +4.94% | |
| Q2 FY2025 | 5.23 | 5.36 | +2.49% | -0.19% | 10.68B | 10.86B | +1.62% | +2.98% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 30.63 | — | — | +10.41% | 53.76B | — | — | +6.33% |
| FY2027 | 27.74 | — | — | +9.71% | 50.57B | — | — | +5.34% |
| FY2026 | 25.29 | — | — | +10.56% | 48.00B | — | — | +7.73% |
| FY2025 | 22.75 | 22.87 | +0.55% | +4.62% | 44.29B | 44.56B | +0.61% | +3.91% |
| FY2024 | 21.70 | 21.86 | +0.73% | +1.49% | 42.77B | 42.88B | +0.25% | +0.05% |
| FY2023 | 21.52 | 21.54 | +0.09% | -7.31% | 42.75B | 42.86B | +0.25% | -4.58% |
| FY2022 | 23.04 | 23.24 | +0.88% | -7.45% | 43.88B | 44.92B | +2.36% | +14.55% |
Thermo Fisher Scientific growth and profitability
Full income statement- Revenue (TTM)
- 47.35B USD
- Net income (TTM)
- 7.08B USD
- Gross margin
- 41.44%
- Operating margin
- 17.98%
- Net margin
- 14.96%
Revenue / Net income
Revenue Net income Net margin
How Thermo Fisher Scientific makes its money
Consumables18.66B 41.9%
Service18.59B 41.7%
Instruments7.30B 16.4%
Revenue44.56B 100.0%
Cost of revenue26.32B 59.1%
Gross profit18.24B 40.9%
Research and development1.40B 3.1%
Selling and administration8.73B 19.6%
Operating income8.11B 18.2%
Tax547.00M 1.2%
Other expense825.00M 1.9%
Net income6.74B 15.1%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Thermo Fisher Scientific revenue breakdown
By product
FY2025
41.9%Consumables41.7%Service16.4%Instruments
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Consumables | 18.66B | 41.9% | +6.1% |
| Service | 18.59B | 41.7% | +4.2% |
| Instruments | 7.30B | 16.4% | -1.9% |
By region
FY2025
51.7%UNITED STATES26.5%Europe18.2%Asia Pacific3.6%All Other Countries
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| UNITED STATES | 23.03B | 51.7% | +2.4% |
| Europe | 11.83B | 26.5% | +8.9% |
| Asia Pacific | 8.10B | 18.2% | +1.8% |
| All Other Countries | 1.60B | 3.6% | +2.3% |
Operating and free cash flow
Full cash flow statementOperating cash flow Free cash flow
Thermo Fisher Scientific financial health
Full balance sheet- Cash and short-term investments
- 6.06B USD
- Total debt
- 41.37B USD
- Net cash
- -35.31B USD
- Free cash flow (TTM)
- 7.60B USD
- Current ratio
- 1.81
- Debt to equity
- 0.76
- Piotroski score
- 7 / 9
- Altman Z-score
- 4.12
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Assets, liabilities and equity
Total assets Total liabilities Shareholders' equity
Thermo Fisher Scientific valuation
- Price to earnings ratio (TTM)
- 37.19
- Forward P/E (FY2026)
- 27.93
- Price to sales (TTM)
- 5.53
- Price to book
- 4.78
- EV / EBITDA (TTM)
- 26.42
Capital structure
Market capitalization
261.70B USD
+
Total debt
41.37B USD
−
Cash and short-term investments
6.06B USD
=
Enterprise value
297.01B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Thermo Fisher Scientific against its own history
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Danaher, Natera, IDEXX Laboratories, Agilent Technologies, Waters, and IQVIA Holdings, the US Medical - Diagnostics & Research companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median37.222.839.7
- Gross marginBelow its median40.9%40.1%50.1%Against its peers: 6 of 7Peers' median 59.4%
- Operating marginAt its median18.2%17.4%26.3%Against its peers: 5 of 7Peers' median 21.1%
- Net marginAt its median15.1%14.0%19.7%Against its peers: 4 of 7Peers' median 16.7%
- Return on equityLowest in 5 years12.6%12.6%18.9%Against its peers: 5 of 7Peers' median 20.1%
- Free cash flow marginLowest in 5 years14.1%14.1%17.9%Against its peers: 5 of 7Peers' median 16.8%
- Revenue growthAt its median3.9%-4.6%21.7%Against its peers: 6 of 7Peers' median 6.9%
- EPS growthAbove its median7.3%-12.4%21.8%Against its peers: 2 of 6Peers' median 3.2%
- Debt to EBITDAHighest in 5 years3.43×2.78×3.43×Against its peers: 5 of 6Peers' median 1.83×
- Current ratioHighest in 5 years1.891.481.89Against its peers: 3 of 7Peers' median 1.80
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Thermo Fisher Scientific dividends
- Annual dividend
- 1.88 USD
- Dividend yield (indicated)
- 0.27%
- Payout ratio
- 9.69%
- Years of dividend growth
- 9
- Frequency
- Quarterly
- Last payment
- 0.47 USD
- Last ex-dividend date
- 15 Sept 2026
- Last payment date
- 15 Oct 2026
Dividends per share
Thermo Fisher Scientific ownership
- Institutions
- 91.40%
- Institutional holders
- 2,714 (+28)
- Free float
- 99.74%
InstitutionsOthers
As of 30 Jun 2026
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 1 | 0.00 | 6.32K |
| Q3 2026 | 0 | 93 | 87.75K | 194.27K |
| Q2 2026 | 0 | 1 | 5.33K | 480.29 |
| Q1 2026 | 0 | 35 | 116.36K | 40.06K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Common questions about Thermo Fisher Scientific's financials
Source: Financial Modeling Prep